Huda Y. Zoghbi - Oct 13, 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role: Director
Signature: /s/** Huda Y. Zoghbi
Stock symbol: REGN
Transactions as of: Oct 13, 2023
Transactions value $: -$458,080
Form type: 4
Date filed: 10/17/2023, 04:06 PM
Previous filing: Jan 5, 2023
Next filing: Jan 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	REGN	Common Stock	Options Exercise	$392K	+1K	+80.19%	$391.92	2.25K	Oct 13, 2023	Direct	F1
transaction	REGN	Common Stock	Sale	-$850K	-1K	-44.5%	$850.00	1.25K	Oct 13, 2023	Direct	F1

Showing 1 to 2 of 2 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	REGN	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-1K	-47.24%	$0.00	1.12K	Oct 13, 2023	Common Stock	1K	$391.92	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023.
F2	The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.